Treatment of psoriasis vulgaris using low-dose naltrexone

Psoriasis is a common, immune-mediated skin disease affecting 3.1% of the US population.1 Psoriasis negatively impacts health-related quality of life and is associated with multiple physical and mental health comorbidities2 in addition to symptoms such as pain, itching, and bleeding. Psoriasis also imparts substantial burden on the national economy, including high health care resource use and direct and indirect costs and contributes to work impairment, presenteeism, and employment status changes because of symptoms.